The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.
The new recommendations retain and combine elements from guidelines published in 2013 and 2017 and, based on extensive review of new data, include important evidenc-based additions and revisions. Top among the new recommendations is a Class 2a recommendation for use of SGLT-2 inhibitors in HFpEF and revised ACC/AHA stages of heart failure.
For primary care clinicians the revised staging of heart failure reinforces a primary focus of the new guidlines on prevention of heart failure; thus the new Stage A: At-risk for heart failure emphasizes early identification of and treatment to reduce risk factors that include a range of cardiometabolic disease.
The Guideline Topline that follows includes the new stages of heart failure and a quick look at the 10 topline guidlines take-home points identified by the writing committe.
Reference: Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guidline for management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am COll Cardiol. 2022. Published online and available at https://www.jacc.org/doi/pdf/10.1016/j.jacc.2021.12.012.